‘Cancer Today’. [Online]. Available: https://gco.iarc.fr/today/home. [Accessed: 29-Jul-2022].

Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. Rev World J Oncol. 2019;10(1):10–27.

Article  Google Scholar 

O’Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur J Surg Oncol. 2008;34(3):324–32.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654. Epub 2021 Jan 12. Erratum in: CA Cancer J Clin. 2021 Jul;71(4):359

Meng Q, et al. Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. J Cancer. 2017;8(17):3615–22.

Article  PubMed  PubMed Central  Google Scholar 

Fahrmann JF, et al. Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection HHS Public Access. Gastroenterol. 2021;160(4):1373–83.

Article  CAS  Google Scholar 

Raptis DA, Fessas C, Belasyse-Smith P, Kurzawinski TR. Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer. Surg. 2010;8(5):239–46.

Google Scholar 

Steinberg W. The clinical utility of the CA 19–9 tumor-associated antigen. Am J Gastroenterol. 1990;85(4):350–5.

CAS  PubMed  Google Scholar 

Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266–70.

Article  CAS  PubMed  Google Scholar 

‘Pancreatic Cancer — Cancer Stat Facts’. [Online]. Available: https://seer.cancer.gov/statfacts/html/pancreas.html. [Accessed: 29-Jul-2022].

L. Rahib, B. D. Smith, R. Aizenberg, A. B. Rosenzweig, J. M. Fleshman, and L. M. Matrisian, ‘Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states’, Cancer Res., vol. 74, no. 11. American Association for Cancer Research Inc., pp. 2913–2921, 01-Jun-2014.

Park W, Chawla A, O’Reilly EM. Pancreatic Cancer: A Review. JAMA. 2021;326(9):851–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kolbeinsson HM, Chandana S, Wright GP, Chung M. ‘Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. J Investig Surg Off J Acad Surg Res. 2023;36(1):2129884.

Google Scholar 

Conroy T, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395–406.

Article  CAS  PubMed  Google Scholar 

Neoptolemos JP, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet (London, England). 2001;358(9293):1576–85.

Article  CAS  PubMed  Google Scholar 

•• L. D. Wood, M. I. Canto, E. M. Jaffee, and D. M. Simeone, ‘Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment’, Gastroenterology, Aug. 2022. Review of the current status of surveillance and early detection of PDAC, including populations at high risk and screening approaches as well as outline of the diagnostic approach to PDAC including key treatment considerations, including how therapeutic approaches change with disease stage and targetable subtypes of PDAC

Chawla A, et al. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. Ann Surg Oncol. 2020;27(4):1191–200.

Article  PubMed  Google Scholar 

Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol. 2014;20(31):10740–51.

Article  PubMed  PubMed Central  Google Scholar 

Huguet F, Dabout V, Rivin Del Campo E, Gaujoux S, Bachet JB. The role of radiotherapy in locally advanced pancreatic cancer. Br J Radiol. 2021;94(1125):20210044.

Article  PubMed  PubMed Central  Google Scholar 

•• F. Pasqualetti et al., ‘Adjuvant radiotherapy in patients with pancreatic adenocarcinoma. Is it still appealing in clinical trials? A meta-analysis and review of the literature’, Anticancer Res., vol. 41, no. 10, pp. 4697–4704, Oct. 2021. The review aimed to assess the impact of postoperative radiotherapy through a meta-analysis of prospective randomized studies.

Chen X, et al. Toll-like receptor 2 and Toll-like receptor 4 exhibit distinct regulation of cancer cell stemness mediated by cell death-induced high-mobility group box 1. EBioMed. 2019;40:135.

Article  Google Scholar 

Gnanamony M, Gondi CS. Chemoresistance in pancreatic cancer: Emerging concepts Revie. Oncol Lett. 2017;13(4):2507–13 (Spandidos Publications).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Golan T, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Laquente B, Calsina-Berna A, Carmona-Bayonas A, Jiménez-Fonseca P, Peiró I, Carrato A. Supportive care in pancreatic ductal adenocarcinoma. Clin Transl Oncol. 2017;19(11):1293–302.

Article  CAS  PubMed  Google Scholar 

Védie AL, Neuzillet C. Pancreatic cancer: Best supportive care. Presse Med. 2019;48(3):e175–85.

Article  PubMed  Google Scholar 

Akizuki N, et al. Prevalence and predictive factors of depression and anxiety in patients with pancreatic cancer: a longitudinal study. Jpn J Clin Oncol. 2016;46(1):71–7.

Article  PubMed  Google Scholar 

Janda M, et al. Anxiety, depression and quality of life in people with pancreatic cancer and their carers. Pancreatol. 2017;17(2):321–7.

Article  Google Scholar 

Clark KL, Loscalzo M, Trask PC, Zabora J, Philip EJ. Psychological distress in patients with pancreatic cancer–an understudied group. Psychooncol. 2010;19(12):1313–13.

Article  Google Scholar 

Holland JC, et al. Comparative psychological disturbance in patients with pancreatic and gastric cancer. Am J Psych. 1986;143(8):982–6.

Article  CAS  Google Scholar 

Mayr M, Schmid RM. Depression in pancreatic cancer: sense of impending doom. Diges. 2010;82(1 Switzerland):1–3.

Article  Google Scholar 

Boyd AD, et al. Screening for depression, sleep-related disturbances, and anxiety in patients with adenocarcinoma of the pancreas: a preliminary study. Sci World J. 2012;2012:650707.

Article  Google Scholar 

Skelton WP, et al. Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. J Gastrointest Cancer. 2017;49(1):1–8.

Article  Google Scholar 

Cederholm T, et al. Diagnostic criteria for malnutrition – An ESPEN Consensus Statement. Clin Nutr. 2015;34(3):335–40.

Article  CAS  PubMed  Google Scholar 

Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2012;10(2):90–9.

Article  PubMed  Google Scholar 

Petruzzelli M, Wagner EF. Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes Dev. 2016;30(5):489–501.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muscaritoli M, et al. Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. Oncotarget. 2017;8(45):79884.

Article  PubMed  PubMed Central  Google Scholar 

Hébuterne X, Lemarié E, Michallet M, De Montreuil CB, Schneider SM, Goldwasser F. Prevalence of Malnutrition and Current Use of Nutrition Support in Patients With Cancer. J Parenter Enter Nutr. 2014;38(2):196–204.

Article  Google Scholar 

Bachmann J, Büchler MW, Friess H, Martignoni ME. Cachexia in patients with chronic pancreatitis and pancreatic cancer: impact on survival and outcome. Nutr Cancer. 2013;65(6):827–33.

Article  PubMed  Google Scholar 

Ozola Zalite I, et al. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: A systematic review. Pancreatol. 2015;15(1):19–24.

Article  CAS  Google Scholar 

Olivares O, Vasseur S. Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze. Int J Cancer. 2016;138(4):787–96.

Article  CAS  PubMed  Google Scholar 

Mayers JR, et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Sci. 2016;353(6304):1161–5.

Article  CAS  Google Scholar 

Muñoz Martín AJ, García Alfonso P, Rupérez Blanco AB, Pérez Ramírez S, Blanco Codesido M, Martín Jiménez M. Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana’s predictive model. Clin Transl Oncol. 2014;16(10):927–30.

Article  PubMed  Google Scholar 

Faille D, et al. Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process. Oncotarget. 2018;9(41):26453–65.

Article  PubMed  PubMed Central  Google Scholar 

‘Traditional, Complementary and Integrative Medicine’. [Online]. Available: https://www.who.int/health-topics/traditional-complementary-and-integrative-medicine#tab=tab_1. [Accessed: 07-Oct-2022].

Kunnumakkara AB, et al. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. 2017;174(11):1325–48.

Article  CAS  PubMed  Google Scholar 

Qi F, et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends. 2015;9(1):16–34.

Article  CAS  PubMed  Google Scholar 

Schwarz K, Dobiasch S, Nguyen L, Schilling D, Combs SE. ‘Modification of radiosensitivity by Curcumin in human pancreatic cancer cell lines. Sci Rep. 2020;10(1):1–10.

Article